Aavon Clinical Trials, LLC. | Richmond, TX

Research site

About

At Aavon, our vision is to lead the way in clinical research by prioritizing integrity, safety, and ethical processes in every aspect of Clinical Research. Our goal is to foster trust and transparency in our research practices, empowering patients and communities with reliable information that drives better health outcomes. Together, we strive to create a healthier future for all, grounded in our unwavering commitment to ethical standards and the highest level of safety

Location

7103 S Peek Rd, Richmond, Texas, United States of America

Website

https://aavonclinical.com

Site insights

Top conditions

Top treatments

Salmeterol Xinafoate

Indacaterol Acetate

ORMD-0801

CNP-103

MANP

QVM149

Glycopyrronium Bromide

Mometasone Furoate

Fluticasone Propionate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Datiobong Udoeyop

Verified by this site

Active trials

7 of 8 total trials

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects with Type 2 Diabetes Mellitus.

ORA-013-3 is a randomized, controlled study to test the efficacy and safety of an oral capsule of ORMD-0801 at several doses in patients with Type 2...

Not yet enrolling

Type 2 Diabetes Mellitus

Other: Placebo capsule

Drug: ORMD-0801 16 mg

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

A double-dummy, double-blind, randomized, parallel-group, active controlled study to evaluate the efficacy and safety of QVM149 (indacaterol acetate...

Begins enrollment in 8 months

Asthma

Drug: Placebo to Salmeterol Xinafoate / Fluticasone Propionate

Drug: Salmeterol Xinafoate / Fluticasone Propionate

Assessment of an Integrated Continuous Glucose Monitor and Insulin Injection Port in Type 2 Diabetes

THE GOALS of the STUDY are: (1) Determine if this novel continuous glucose monitoring (CGM) - multiple daily injection (MDI) port functions for 7 day...

Begins enrollment in 3 months

Type 2 Diabetes Treated With Insulin

Device: Use of novel insulin injection port

CNP-103 in Adolescent and Adult Subjects Ages 12-35 with Recently Diagnosed (within 6 Months) Stage 3 Type 1 Diabetes (T1D)

This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple a...

Not yet enrolling

Type 1 Diabetes Patients

Type 1 Diabetes Mellitus

Drug: CNP-103

Drug: Placebo

Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes (ReCET)

This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabet...

Enrolling

Diabetes

Type2diabetes

Device: ReCET Treatment

Device: Sham Procedure

SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes

The purpose of this study is to find out how well a new continuous glucose monitor works for people with diabetes. This study will test the performan...

Not yet enrolling

Type 1 Diabetes Mellitus

Type 2 Diabetes Mellitus

Device: Continuous Glucose Monitoring

To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension (BOLD-HTN)

This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing ba...

Enrolling

Difficult to Control Hypertension

Drug: MANP

Other: Placebo Matched control

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms